Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention.
about
Thermodynamic analysis of Jun-Fos coiled coil peptide antagonistsBio-inspired strategies for designing antifouling biomaterialsPhysiology and pathophysiology of the blood-brain barrier: P-glycoprotein and occludin trafficking as therapeutic targets to optimize central nervous system drug deliveryPreclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s DiseaseThe E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6In silico study of peptide inhibitors against BACE 1.Truncated and helix-constrained peptides with high affinity and specificity for the cFos coiled-coil of AP-1Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas.In vitro methods for peptide display and their applications.Truncation, randomization, and selection: generation of a reduced length c-Jun antagonist that retains high interaction stabilityTargeting protein-protein interactions as an anticancer strategyFunctional characterization of a competitive peptide antagonist of p65 in human macrophage-like cells suggests therapeutic potential for chronic inflammation.Combining intracellular selection with protein-fragment complementation to derive Aβ interacting peptides.Novel retro-inverso peptide inhibitor reverses angiotensin receptor autoantibody-induced hypertension in the rabbitDesigning of peptides with desired half-life in intestine-like environment.Cone snail venomics: from novel biology to novel therapeutics.Library construction, selection and modification strategies to generate therapeutic peptide-based modulators of protein-protein interactions.High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs AntagonistsA Barcoding Strategy Enabling Higher-Throughput Library Screening by MicroscopyNovel 3-(1H-indol-3-yl)-2-[3-(4-methoxyphenyl)ureido]propanamides as selective agonists of human formyl-peptide receptor 2Rapid and reversible knockdown of endogenous proteins by peptide-directed lysosomal degradation.Chemical modulation of bioactive compounds via oligopeptide or amino acid conjugation.Review cyclic peptides on a merry-go-round; towards drug design.Short peptides interfering with signaling pathways as new therapeutic tools for cancer treatment.The Potential Therapeutic Application of Peptides and Peptidomimetics in Cardiovascular Disease.Radiosynthesis and in vivo Evaluation of Carbon-11 (2S)-3-(1H-Indol-3-yl)-2-{[(4-methoxyphenyl)carbamoyl]amino}-N-{[1-(5-methoxypyridin-2-yl)cyclohexyl]methyl}propanamide: An Attempt to Visualize Brain Formyl Peptide Receptors in Mouse Models of NeuA novel peptide stapling strategy enables the retention of ring-closing amino acid side chains for the Wnt/β-catenin signalling pathway.β(3R3)-Peptides: design and synthesis of novel peptidomimetics and their self-assembling properties at the air-water interface.Peptide Mimetic Drugs for Modulating Thrombosis and Hemostasis.Ester vs. amide on folding: a case study with a 2-residue synthetic peptide.A peptidomimetic inhibitor suppresses the inducibility of β1-adrenergic autoantibody-mediated cardiac arrhythmias in the rabbit.Toward peptide-based inhibitors as therapies for Parkinson's disease.Interaction of multiple biomimetic antimicrobial polymers with model bacterial membranes.Design and Stereoselective Synthesis of ProM-2: A Spirocyclic Diproline Mimetic with Polyproline Type II (PPII) Helix Conformation.Vicinal Disulfide Constrained Cyclic Peptidomimetics: a Turn Mimetic Scaffold Targeting the Norepinephrine TransporterConformational Design and Characterisation of a Truncated Diamine Oxidase from
P2860
Q24322769-43141BD7-5799-4F86-B5A1-C71D736CC39AQ26744168-D2075C86-4732-4FB1-BA80-2F1DA61152BDQ26861408-4164CF96-1C7D-4586-A8E1-BB02F0FA9F0CQ27305174-4AB88DCD-593B-42F9-B817-4DB5802BBF76Q28544832-14FC1C47-AA52-4C6D-A13E-5C88E8F4232AQ30374668-4EDEC310-A326-46A8-A7F6-0AA563F50B73Q30610173-4242CD4A-83A0-4F53-A991-A6AE3B31F075Q33683537-03EC059D-598B-40CE-AE5C-C2B26023555DQ33917861-0D749042-9CF8-48C7-97AF-499117ED92BBQ33940327-83D95218-51C7-4B7E-A3B2-CB7DE0CF9F2BQ34347892-AAFBABE5-16AD-4CE4-B35F-9435D3DC0B6EQ34672342-9B001AE4-F53A-4C48-8C93-A5AC8860C881Q34740753-D90C3B2C-EF91-4697-8BFD-8B23462DD3E7Q35175458-D981D346-0E64-44C9-9F31-2BCE8EE0E828Q35228840-ED9890B4-D6EC-44BA-8531-3B86509E378CQ35432836-0020F648-5843-4010-9C1F-EF3D8B841953Q35532355-E3160D66-3D0C-4525-A07E-45C299B7D1A3Q35634594-BF3B542F-B3D9-481E-8C70-11DFA92EF5FEQ35686321-EBB8BFAC-79F3-4096-B5B7-1647EE6D8BB3Q35738729-F61F9EAC-CC65-4244-829B-8AA461BF9C6FQ37607614-456FE3A6-D685-448D-B0CC-C22C5FDD99F4Q38124818-491D0287-1A87-4087-A290-57456EB7D0B4Q38476515-222BB15D-FE9F-4422-980E-20F20C20C3D4Q38767147-B05C5F17-72CD-4409-9952-0F8A0DB90890Q38767234-57BD98BA-DF1A-4210-9FC3-BDD86DEE3F35Q38859451-19BC5F5F-7F7F-4072-9538-58F2F1F8C4B8Q43882044-F99131C2-DA69-4C3B-90B6-8AD95A4A6D9BQ44501775-F7A567CB-BEAC-4747-898F-257975F1B5D4Q44874794-E065AA8E-2C70-417E-819B-3316DC342D03Q45329378-20C19FCF-7FD0-4BB7-A5F3-1CFB5CF6B632Q48073010-47F9E98A-9DDD-425A-B79E-CDD6EC7B924DQ48340201-BF723F3C-2458-4C52-AE30-F67B811C03D3Q51046016-1C091D11-7E45-46AC-A06A-25088C2C92B5Q52867387-CFB0536C-DE5F-4453-9EBC-2BA75809DC6EQ58284578-91ADC42C-6B28-4965-B334-A110EE8EB224Q58702645-A172257A-F542-4C19-BB73-CDE929AFEDF2
P2860
Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Design and development of pept ...... for therapeutic intervention.
@en
Design and development of pept ...... for therapeutic intervention.
@nl
type
label
Design and development of pept ...... for therapeutic intervention.
@en
Design and development of pept ...... for therapeutic intervention.
@nl
prefLabel
Design and development of pept ...... for therapeutic intervention.
@en
Design and development of pept ...... for therapeutic intervention.
@nl
P2860
P356
P1476
Design and development of pept ...... for therapeutic intervention.
@en
P2093
Jody M Mason
P2860
P304
P356
10.4155/FMC.10.259
P577
2010-12-01T00:00:00Z